Industry Outlook

The Liquid Biopsy market accounted for USD 8.4 Billion in 2024 and is expected to reach USD 33.82 Billion by 2035, growing at a CAGR of around 13.5% between 2025 and 2035. The Liquid Biopsy Market is part of a diagnostic industry that identifies cancer through minimally invasive blood tests. It uses other markers to identify the features of circulating tumor cells (CTCs) or free DNA extracted from blood. Some advantages include early detection, real-time cancer monitoring, and evaluating how the treatment is responding.  Moreover, keeping an eye on hereditary changes and the process of drug resistance is crucial. This includes real-time tracking of illness and personalized therapeutic planning. Consequently, the market is expanding quickly attributed to technological improvements, more cancer incidences, and increasing popularity of precise oncology techniques.

Report Scope:

Market Dynamics

Precision medicine demands personalized, non-invasive liquid biopsy techniques.

The transformation of precision medicine towards personalized healthcare has become a growth factor of the liquid biopsy market, with increasing demand for specific non-invasive diagnostic approaches. Liquid biopsy is a less invasive option than traditional tissue biopsy because it can detect exosomes, RNA, and circulating tumor DNA (ctDNA). Consequently, this kind of test is used for early disease detection. It is also helpful in monitoring patients who are under treatment and predicting relapses. This can be performed painlessly as compared to risky and painful tissue biopsies, which improve patient adherence.

Governments and educational institutions are supporting the growth of liquid biopsy technologies. For instance, The U.S. National Cancer Institute’s Cancer Moonshot Initiative hopes to reduce cancer deaths by half within 25 years through non-invasive diagnostic methods, including liquid biopsies. In Europe, there are a few programs, such as the European Liquid Biopsy Academy (ELBA), which is funded under EU’s Horizon 2020 research framework and aimed at promoting clinical uptake of these technologies.

High test costs limit liquid biopsy access in developing regions.

The elevated prices related to tests are a major obstacle to the availability of liquid biopsy in underdeveloped areas. This reduces universal uptake and utilization. This innovative diagnostic tool, aimed at early cancer detection and personalized treatment development, remains prohibitively expensive. The high prices are due to the advanced technologies and expensive laboratory settings needed for its operation. Several developing nations have poorly funded health systems that have become unattainable by either patients or practitioners. Access limitations to liquid biopsy leads to delayed diagnosis and treatment, which contributes to widening health gaps in these regions.

According to the World Health Organization (WHO), cancer is a leading cause of death worldwide, with nearly 10 million deaths in 2020. They do not get an early diagnosis in low- and middle-income countries because they are too expensive, including liquid biopsy. Such financial constraints block personal access and large population health programs meant for diagnostics into routine care services. Achieving progress in meeting this challenge will be useful in ensuring equitable healthcare and allowing the incorporation of cutting-edge diagnostics into developing markets.

AI integration improves data accuracy and automated liquid biopsy diagnostics.

AI communication with liquid biopsy diagnostics provides an opening for changing the marketplace. The artificial intelligence accurately analyzes data regarding cancerous cells, circulating tumor DNA (ctDNA), and other blood sample biomarkers. Compared to regular biopsy, it results into quicker, non-invasive, and more accurate diagnosis. AI can increase the chance of detection and detect early-stage cancers which ultimately improve survival rates by optimizing therapy regimens.

According to the National Cancer Institute (NCI), liquid biopsy technologies can potentially increase the early detection of cancers by about 25% through the use of AI-driven platforms, implying the great worth of artificial intelligence with regard to healthcare innovation. Supported by governments and institutions alike, AI-powered liquid biopsy diagnostics could change cancer therapies forever through more precise and timely data, making it an alluring path for market expansion.

Industry Experts Opinion

“We’re excited to showcase BioMark’s innovative liquid biopsy technology on a global stage. As we prepare for the commercial launch of our early lung cancer assay, this prestigious conference offers a valuable opportunity to connect with potential investors, partners, and industry experts, as we continue to build momentum toward our U.S. market entry.”

• Rashid Bux, CEO and President of BioMark.

“Less than 6% of pancreatic cancer cases are detected today in early stages, when they can be removed with surger. If we manage to double or even quadruple this percentage, more patients will survive. That’s why we want to detect pancreatic cancer years before symptoms appear. Symptoms occur at late stages.”

• Klaus Pantel, coordinator of PANCAID and director of the Institute of Tumor Biology at the University Medical Center Hamburg-Eppendorf (Germany).

Segment Analysis

Based on the product type, the Liquid Biopsy Market has been classified into Assays and Kits, Instruments, and Services. Assays and kits are the most prominent segment. This is because they are an essential part of the liquid biopsy process and provide important instruments for detecting biomarkers in blood samples. Their widespread usage is driven by their capacity to deliver rapid, precise, and non-invasive diagnosis and cancer monitoring. In addition, there is a growing demand for early cancer detection and precision medicine, which continues to propel Assays and Kits in this marketplace.

Based on the application, the Liquid Biopsy Market has been classified into Early Cancer Detection, Recurrence Monitoring, Prenatal Testing, Organ Transplant Monitoring, and Others. Early detection of cancer is the dominant segment, due to the increasing need for non-invasive diagnostic approaches. That helps to identify cancer at an early stage and improve treatment results and survival rates. With the increasing global prevalence of cancer, use of liquid biopsy for early detection is rapidly gaining success and fueling significant growth in this application segment.

Regional Analysis

The North American liquid biopsy market is undergoing extensive growth because of advancements in cancer diagnostics, the growing prevalence of cancer, and the rising uptake of minimally invasive diagnostic techniques. This region is primarily dominated by the U.S. due to its strong healthcare infrastructure, significant research funding, and key firms like Guardian Health, Illumina, and Thermo Fisher Scientific. With more precision medicine awareness and practice in Canada, this country is also contributing to the market expansion. This region’s market is being driven by government initiatives, favorable regulatory policies, and an increasing need for early-stage detection of cancer.

Europe has witnessed numerous research projects and innovations in the domain of liquid biopsy due to advancements in oncology and precision medicine. The foremost nations regarding the use of liquid biopsy technologies for early cancer detection and monitoring the efficiency of treatment are Germany, France, and the UK, among others. Some initiatives for promoting innovation are regulations like CE Marking, which also ensure safety standards for these products across Europe. Moreover, an increasing rate of cancer cases is reported, together with an increase in preference for less invasive approaches toward diagnosis. That creates favorable conditions for this sector to expand rapidly over time. Some new partnerships are being formed among academic institutions, biotech firms, and healthcare entities within the region for expanding liquid biopsy applications to different cancer types.

Competitive Landscape

The demand for liquid biopsy is increasing due to significant gains with non-invasive cancer diagnostics and monitoring solutions. Key players operating in the market include Guardant Health, Qiagen, Illumina, Thermo Fisher Scientific, and F. Hoffmann-La Roche, who have extensive strengths within molecular diagnostics. Grail, Inivata, and Adaptive Biotechnologies are emerging players working on NGS sequencing and ctDNA testing to make a difference.

The launch of Guardant Health's first FDA-approved liquid biopsy test, Guardant360 CDx, to identify gene mutations linked to cancer. This is a great example of precision medicine and ultimately on-the-spot information regarding tumor dynamics without relying upon invasive tissue biopsies. Increasing collaborations between biotech companies and the pharmaceutical sector will further boost market growth through the association of liquid biopsy with targeted therapies and personalized treatment.

Liquid Biopsy Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In February 2024, Twist Bioscience Corporation revealed a kit for preparing cfDNA libraries to aid in liquid biopsy investigations.
• In November 2023, the new TruSight Oncology 500 ctDNA v2, a new generation of its liquid biopsy assay for genomic profiling, was announced by Illumina Inc.
• In January 2023, Agilent Technologies, Inc. purchased Avida Biomed. It is anticipated that this initiative will lead to its rapid growth in the clinical research and diagnostics markets.

Report Coverage:

By Product Type

• Assays and Kits
• Instruments      
• Services

By Application

• Early Cancer Detection 
• Recurrence Monitoring 
• Prenatal Testing
• Organ Transplant Monitoring     
• Others

By Biomarker Type

• Circulating Tumor Cells (CTCs)
• Circulating Tumor DNA (ctDNA)
• Microvesicles   
• Others 

By Technology

• Polymerase Chain Reaction (PCR)        
• Next-Generation Sequencing (NGS)      
• Microarray                    
• Others

By Indication

• Lung Cancer
• Breast Cancer  
• Colorectal Cancer
• Prostate Cancer            
• Pancreatic Cancer        
• Prenatal testing
• Others

By End-User

• Hospitals and Clinics
• Diagnostic Laboratories
• Pharma & Biotech Companies
• Research Institutes

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• Guardant Health, Inc.
• Biocept, Inc.
• Qiagen N.V.
• F. Hoffmann-La Roche Ltd.
• Thermo Fisher Scientific Inc.
• Illumina, Inc.
• Adaptive Biotechnologies Corporation
• Exact Sciences Corporation
• Freenome Holdings, Inc.
• Natera, Inc.
• Personal Genome Diagnostics, Inc.
• MDxHealth SA
• Grail, Inc.
• Foundation Medicine, Inc.
• Inivata Limited

Frequently Asked Questions (FAQs)